Request for Information Prophylactic Platform Technologies for Medical Countermeasures

W911SR-26-S-PPFC – Prophylactic Platform Technologies for Medical Countermeasures

1.0 Purpose

The Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense (PME CBRND), through the Chemical, Biological, Radiological, Nuclear (CBRN) Medical - Accelerated Defense Pharmaceuticals (ADP) program, is seeking information from qualified commercial and academic product developers.
The ADP program requests information regarding the design, manufacturing, non-clinical testing, and clinical testing of advanced prophylactic platform technologies directed against one or more specific CBRN threats of concern (see Appendix 1 below). The intent is to understand industry capabilities to accelerate platform innovation and/or expansion of an existing platform technology, support rapid response against biological and chemical threats, and progress existing candidate platforms toward Phase I or Phase II clinical trials regulatory and operational milestones.

2.0 Background

The JPM for CBRN Medical, operating under the PME CBRND, serves as the Department of War’s (DoW) premier program management office for the development, acquisition, and fielding of safe, effective, and innovative medical solutions to safeguard service members against CBRN threats. JPM CBRN Medical leads medical countermeasure (MCM) development across three operational pillars:
Prophylactic Platforms (pre-exposure and post-exposure prophylaxis) Diagnostics (rapid detection and clinical identification) Therapeutics (post-exposure medical intervention)
These pillars form critical elements of an integrated, layered defense strategy. Within this portfolio, the ADP program focuses on accelerating the timeline from threat identification to safe, scalable, and deployable prophylactic platform countermeasure availability. The primary objective of this initiative is to advance to Phase I or Phase II clinical trials the maturation of existing prophylactic MCMs built on proven platform technologies that have established clinical safety profiles and/or demonstrate robust preclinical immunogenicity, safety, and efficacy data.
The objective of the program is to progress the development of existing prophylactic MCMs manufactured on existing platform technologies that support clinical safety and/or possess strong preclinical immunogenicity, safety, and efficacy data. Development of the prophylactic MCM will be through a modular approach completing through Phase I or Phase II clinical trial while